PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

Table 2 PR104 starting and maximal tolerated doses with its combination agents, their doses and administration schedules

Group	PR104 dose (mg/m²)		Combination Agents		Schedule
Group	Starting	Maximum tolerated	Agent	Dose (mg/m²)	Schedule
A	275	140	Gemcitabine	800	iv days 1 and 8 q 3 weekly
B	400	<200	Docetaxel	60	iv day 1 q 3 weekly
C	200	770	Docetaxel + G-CSF	60	iv day 1 q 3 weekly
D	770	≥770	Docetaxel + G-CSF	75	iv day 1 q 3 weekly

ISSN: 1471-2407